Skip to content

Merck’s Keytruda nabs two nods in Japan

August 24, 2020

The Japanese Ministry of Health, Labor and Welfare’s Pharmaceuticals and Medical Devices Agency has approved Merck’s (NYSE:MRK) Keytruda (pembrolizumab) for patients with PD-L1-positive resectable, advanced or recurrent esophageal squamous cell carcinoma who have progressed after chemo.

The regulator also approved a new dosing regimen for the PD-1 inhibitor, 400 mg every six weeks as an intravenous infusion over 30 minutes across all adult indications (original regimen, still available, is 200 mg every three weeks).

From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: